Introduction
============

According to the Pharmaceutical Care Network Europe definition, "Pharmaceutical care is the pharmacist's contribution to the care of individuals in order to optimize medicines use and improve health outcomes".[@b1-ppa-10-2239] The community pharmacist's role has recently been extended from just dispensing to providing guidance in pharmaceutical care. Several pharmaceutical care programs and activities have been developed to educate and counsel patients with (chronic) medication use, showing some promising results in improving outcomes such as disease control and medication adherence.[@b2-ppa-10-2239]--[@b5-ppa-10-2239]

Patients with asthma and chronic obstructive pulmonary disease (COPD) could especially benefit from these activities. Around 40% of them fail to take their inhaled corticosteroids (ICS) as prescribed.[@b6-ppa-10-2239] Regular ICS treatment reduces symptoms and the frequency of exacerbations and enhances lung function and quality of life.[@b7-ppa-10-2239],[@b8-ppa-10-2239] Taking less medication than prescribed (suboptimal adherence) leads to poor disease control, morbidity, mortality, and high health care costs.[@b6-ppa-10-2239] Many patients with asthma (17%--57%) do indeed have poor disease control,[@b9-ppa-10-2239] as shown by the high rates of emergency-room visits and hospital admissions.[@b10-ppa-10-2239]

Sufficient and correct knowledge about the disease and medication is needed to achieve better adherence to antiasthma drugs and have better asthma control.[@b11-ppa-10-2239],[@b12-ppa-10-2239] But the knowledge among patients with asthma appears suboptimal.[@b13-ppa-10-2239] Many patients report taking their medication only when they think they should or when they experience shortness of breath.[@b14-ppa-10-2239] In addition, 70% of patients using ICS apply incorrect inhaler techniques that disenable total absorption of the medication in the lungs.[@b15-ppa-10-2239] Improving inhaler technique is likely to improve symptom control.[@b16-ppa-10-2239]

Clearly, educating patients with asthma and COPD about their disease, medication use, and inhalation technique is of great importance in enhancing ICS adherence and symptom control. This is even more so as patients' potentially modifiable medication beliefs are related to ICS adherence.[@b17-ppa-10-2239]--[@b19-ppa-10-2239] Patients who have many concerns and misconceptions about ICS (eg, about side effects and drug dependency) are more inclined to be nonadherent. Therefore, health care providers should try to diminish patients' concerns and strengthen their ICS necessity beliefs,[@b17-ppa-10-2239],[@b19-ppa-10-2239] by showing empathy and providing reassurance and information about ICS use and adherence. However, medication adherence is hardly addressed at all in clinical encounters,[@b20-ppa-10-2239],[@b21-ppa-10-2239] even though Zolnierek and Dimatteo[@b22-ppa-10-2239] showed that the odds of patient adherence are 2.16 times higher when a physician communicates effectively.

To perform their new role as communicators, pharmacists and pharmacy technicians receive training in patient education and communication in undergraduate and postgraduate courses.[@b23-ppa-10-2239] However, so far, little is known about the extent to which they actually apply these skills in counseling sessions.[@b24-ppa-10-2239] Recent research indicates that pharmacists focus mainly on biomedical issues and pay little attention to psychosocial issues.[@b25-ppa-10-2239],[@b26-ppa-10-2239]

In counseling sessions, pharmacists or technicians can discuss patients' experiences with (chronic) medication, usually in a private consulting room at the community pharmacy. Although some pharmacies do offer counseling sessions to patients about their ICS use, these sessions are not common practice in the Netherlands yet.[@b23-ppa-10-2239],[@b27-ppa-10-2239] Furthermore, it is unknown whether pharmacists and technicians are equally able to conduct these sessions. For instance, there are differences in the undergraduate and postgraduate courses for pharmacists and technicians. As technicians have more frequent contacts with patients than pharmacists,[@b28-ppa-10-2239] they might be more experienced in patient communication. A study of patients' perceived barriers in communication with their health care provider revealed that patients experience fewer barriers to participation in a visit with a nurse than with a physician.[@b29-ppa-10-2239] This might also apply to pharmacists and technicians, with fewer barriers in talks with technicians. However, pharmacists might have a more persuasive communication style by virtue of their position, as they are the managers and often owners of the pharmacy. Getting insight into the differences in the communication content and process might have relevance for session and patient outcomes and might indicate who is most capable of performing these counseling sessions and who might need additional communication training.

The aim of this study was therefore to explore 1) how pharmacists and pharmacy technicians communicate with patients with asthma and/or COPD about ICS during a counseling session (communication process); 2) what topics are discussed during these sessions (communication content); and 3) to what extent pharmacists and technicians differ in their communication. Based on practice guidelines about asthma and COPD, we thereby focus especially on the following communicative aspects:[@b30-ppa-10-2239]--[@b32-ppa-10-2239] affective communication (eg, showing empathy and giving reassurance), providing information about asthma/COPD and ICS, discussing adherence, inhalation technique, side effects, concerns, and necessity beliefs about ICS, and lifestyle topics (eg, smoking and exercise).

Materials and methods
=====================

Setting
-------

This observational study is part of a larger research project examining the communication of community pharmacists and technicians with patients with asthma and/or COPD, which was performed between September 2011 and February 2012. Data were collected with the help of pharmacists belonging to the Utrecht Pharmacy Practice Network for Education and Research (UPPER), and the work was conducted in compliance with the requirements of the UPPER institutional review board of the Department of Pharmacoepidemiology and Clinical Pharmacology. A total of 130 community pharmacies were approached via email by UPPER and invited to participate, with 12 pharmacies actually participating. No selection criteria were applied for pharmacies' participation.

Per pharmacy, recruited patients were randomly assigned to an intervention group or a control group. Randomization was performed using a statistical program (Stata Version 12.1), which generated lists consisting of a random series of 0s and 1s. We generated a separate list for each pharmacy. A "0" referred to assignment to the control group, and a "1" referred to assignment to the intervention group. By following the order of the numbers on the list, patients were assigned to the two groups in the sequence of their registration for participation.

Patients in the intervention group had a counseling session at the community pharmacy; patients in the control group had no session and only completed questionnaires. For the purpose of this study, only data from patients who had a counseling session were used.

At each participating pharmacy, one pharmacist and one pharmacy technician performed individual counseling sessions with patients with asthma and/or COPD. Each pharmacist selected a pharmacy technician from his/her own team, so 12 pharmacists and 12 technicians held sessions. Each patient had one session with either a pharmacist or a pharmacy technician. The number of counseling sessions depended on the number of participating patients in that particular pharmacy and on an agreed maximum number of participants per pharmacy.

To get an authentic impression of pharmacists' and technicians' communication styles, only general instructions were provided about the counseling sessions, that is, "discuss the patient's experience with ICS use, the effectiveness and (possible) side-effects of ICS, and whether the patient uses ICS in an appropriate way".

Ethical approval
----------------

The Medical Ethics Committee of the University Medical Center Utrecht assessed the research proposal and concluded that ethical approval was not required because the study did not fall within the remit of the Law on Medical Scientific Research involving Human Beings.

Participants
------------

Patient recruitment took place through the participating pharmacies. Anatomical Therapeutic Chemical classification system codes for ICS and combination products of β2-agonists and ICS were used to determine in the pharmacy system to which patients' ICS had been dispensed. Patients were eligible if they were aged 18 years or older, had been diagnosed with asthma or COPD (based on self-report), had been using ICS for at least 1 year, and had filled two or more ICS prescriptions in the preceding year. Patients living in an institution were excluded because they might receive other or additional care and counseling, which might influence the generalizability of the study results. Patients did not receive a reimbursement for participation.

Procedure
---------

At each pharmacy, all eligible patients were invited to participate in the study, up to a maximum of 200 patients per pharmacy. If there were \>200 eligible patients, a random subset of 200 patients were selected. An information pack was sent by post to 1,952 potentially eligible patients by their pharmacist, containing an invitation letter, a questionnaire, and an informed consent form. Patients were informed about the procedure and the videotaping of the consultations, and they had the opportunity to ask questions about the study and the videotaping of the session before consenting to participation. The completed questionnaire and a signed informed consent form had to be returned for study participation. A researcher contacted the participants by phone to make an appointment for a counseling session with a pharmacist or technician within 2 months after inclusion. The schedules for pharmacists and technicians had been determined beforehand. Depending on patients' preferences for a date or time for an appointment, the consultation was scheduled. These sessions were performed in Dutch, took place in a private room, and were recorded by an unmanned camera, which was directed at the pharmacist or technician.

Materials and measurements
--------------------------

### Questionnaire

The questionnaire consisted of questions about sociodemographics, the medical indication for the ICS prescription (asthma/asthma symptoms and/or COPD or unknown), and other questions related to the patient's medical condition and ICS use.

### Communication measurements

Analyses of the video-recorded sessions were performed using an extended version of the Roter interaction analysis system (RIAS). RIAS is a validated instrument for coding both provider and patient communication, applicable to the pharmacy setting.[@b33-ppa-10-2239]--[@b35-ppa-10-2239] Each small meaningful unit of speech (an utterance) is coded.

RIAS distinguishes two categories of communication: 1) affective or socioemotional communication and 2) instrumental communication, further divided into task- and process-oriented communication. Affective communication includes expressions of empathy, concern, optimism, and understanding, which contribute to a therapeutically effective provider--patient relationship.[@b36-ppa-10-2239] Instrumental communication focuses on the exchange of medical and psychosocial information and advice (task-oriented communication) and process-oriented utterances that guide the process of the conversation, like giving instructions (ie, "orientations").

The four main task-oriented RIAS categories are 1) medical, 2) therapeutic, 3) lifestyle/social, and 4) psychosocial. For the purpose of this study, the task-oriented categories were further divided into 36 content categories, including asthma- and COPD-specific items derived from existing communication literature and guidelines for asthma and COPD,[@b31-ppa-10-2239] from the consumer quality index asthma/COPD,[@b30-ppa-10-2239] and from the Dutch pharmacy COPD guideline.[@b32-ppa-10-2239] This literature was used to indicate topics that are relevant for patients with asthma and/or COPD and that could be discussed during counseling sessions. Examples of specific medical and therapeutic content categories are medical history, current health status, ICS side effects, and ICS adherence. Each main category furthermore had one "residual category" for utterances that belonged to that particular main category but did not fit into any of the specified categories (ie, "medical, other", "ICS, other", "lifestyle, other", and "psychosocial ICS, other"). Utterances about the study or comments about the recording were labeled as "other". For each task-oriented utterance, it was established whether it concerned a question ("question"), the provision of information ("giving information"), or an advice for the patient to change behavior ("counseling") ([Table S1](#SD1-ppa-10-2239){ref-type="supplementary-material"}).

Furthermore, the proportion of utterances made by the pharmacists, pharmacy technicians, and patients was determined as a global indicator of conversational contribution.

The videotapes were coded by three coders from the research team. Observer XT7 software was used to code the communication directly from the videotapes.[@b37-ppa-10-2239]

Interrater reliability
----------------------

Interrater reliability was tested using the intraclass correlation coefficient (ICC) and calculated for all main categories with a mean frequency \>2%, except for the "other" categories.[@b38-ppa-10-2239] One coder recoded a random 10% of the two main coders' consultations. ICC reliability averaged 0.85 (range 0.37--0.98) for pharmacist and technician categories and 0.89 (0.70--0.97) for patient categories, which indicates moderate to good reliability, except for the category "orientations", which had an ICC of 0.37. Given the low ICC of the orientations category, no results are reported for this category.

Statistical analysis
--------------------

Multilevel analysis was carried out to allow for the clustering of patients in pharmacies. Weighted mean and standard errors of all communication categories were calculated for pharmacists and technicians separately and have been reported. To control for visit length, weighted mean per category was divided by the total number of utterances and multiplied by 100%.

Furthermore, we calculated the number of sessions in which a particular content category was mentioned by the pharmacist or the technician once only, more than once, or not at all, whether as a question, piece of advice, or information. Analyses were performed using MLwiN Version 2.25. To determine whether patients' sociodemographic characteristics differed between the pharmacists' sample and those of pharmacy technicians, two-sample proportion tests and Student's *t*-tests were performed using Stata Version 12.1. Descriptive statistics were calculated using Stata Version 12.1.

Results
=======

Study sample
------------

A total of 429 patients returned a completed consent form and questionnaire. One hundred and ninety-nine patients were assigned to the intervention group, of whom 30 patients (15.1%) dropped out for one of the following reasons: they could not be reached by phone/email, involuntary withdrawal (eg, due to poor health), were no longer using ICS, had recently had a session about ICS or asthma, or did not want to participate after all. One hundred and sixty-nine patients received a counseling session at their pharmacy. Of these, 93 patients (55.0%) were female and 76 (45.0%) male. The mean age was 63.1 years (SD =13.9). Half of the 12 pharmacists were male and all the 12 technicians were female. The mean age of the pharmacists was 36.7 years (SD =11.5), and the mean age for technicians was 35.4 years (SD =11.9) ([Table 1](#t1-ppa-10-2239){ref-type="table"}). The pharmacists performed 7.2 sessions on average (range: 3--11 sessions) and pharmacy technicians 6.9 sessions (range: 3--10 sessions). The sociodemographic characteristics of patients in the pharmacists' sample did not differ significantly from those in the pharmacy technicians' sample.

Counseling sessions
-------------------

Pharmacists' counseling sessions lasted significantly longer than those of pharmacy technicians (mean ± standard error: 16.46±0.80 minutes and 11.34±0.80 minutes, respectively; *P*\<0.001). Both categories of professionals talked more than patients in terms of the percentage of utterances (pharmacists accounted for 55.0% of the utterances in their sessions, technicians 53.2%), and most of the communication consisted of instrumental talk ([Table 1](#t1-ppa-10-2239){ref-type="table"}).

Affective and process-oriented communication
--------------------------------------------

[Table 2](#t2-ppa-10-2239){ref-type="table"} shows the weighted mean of the affective and process-oriented communication behaviors per counseling session. Pharmacists and technicians mainly exhibited social behavior, expressed approval and agreement, and gave verbal attention and reassurance to patients. Patients showed similar behaviors and also expressed concerns or worries. With respect to process-oriented communication, pharmacists and technicians paraphrased and checked for understanding and asked the patient for an opinion at least once per session. Patients mainly paraphrased and checked for understanding.

Task-oriented communication
---------------------------

Several medical and therapeutic topics were discussed during the counseling sessions ([Tables 3](#t3-ppa-10-2239){ref-type="table"} and [4](#t4-ppa-10-2239){ref-type="table"}). In the following paragraphs, we describe the topics on which on average at least one utterance per session was made by pharmacists, technicians, or patients.

Medical and therapeutic communication
-------------------------------------

Pharmacists and technicians made at least one utterance per session about each of the following topics: "medical, other", inhaler and inhalation technique, non-ICS treatment (other medication used by the patient), ICS medicinal effects, side effects, dosage and time of inhalation of ICS, current health status, adherence to ICS, reason for use, and "ICS, other". In contrast to technicians, pharmacists also asked at least once about patients' current health status and medical effects, and gave information about explanation about asthma/COPD more than once.

Patients made at least one utterance per session about the following issues: inhaler and inhalation technique, non-ICS medication, "medical, other", dosage and time of inhalation, current health status, medical history, side effects, contact with health care providers about asthma/COPD, "ICS, other", ICS medicinal effects, ICS adherence, lung function test, contact with other health care providers about ICS, and reason for use.

### Lifestyle and social context communication

Pharmacists gave some social context information, but other lifestyle and social context topics were not mentioned more than once. Patients gave information about physical activity, social context, the (living) environment, and "lifestyle, other".

### Psychosocial/feelings communication

Concerning psychosocial information, patients gave information about how they felt about non-ICS medication and "ICS, other". Pharmacists and technicians addressed almost no psychosocial topics.

Differences in communication between pharmacists and pharmacy technicians in their sessions
-------------------------------------------------------------------------------------------

Below, we describe the differences between pharmacists and pharmacy technicians in communication during the counseling sessions. Only significant differences (*P*\<0.05) are reported.

Pharmacists used more affective utterances per session on average than technicians. Patients did not differ in the number of affective utterances in their communication with pharmacists or technicians, except for giving agreements. Patients agreed more frequently in sessions with pharmacists than with technicians.

With respect to process-oriented communication, pharmacists and technicians differed in the number of utterances paraphrasing/checking for understanding. Patients had the same number of process-oriented utterances during sessions with pharmacists and technicians.

### Medical and therapeutic information

The pharmacists were more likely to ask questions about the following topics than the technicians: patients' current health status, reason for ICS use, and other medication. Questions about side effects were asked more often by technicians than by pharmacists. Patients were more likely to ask questions about dosage and time of inhalation of ICS during sessions with pharmacists than with technicians. Pharmacists were more likely to give information about a lung function test, asthma/COPD, reason for ICS use, dosage and time of inhalation, ICS effects, inhaler and inhalation technique, and other medication. Patients were more likely to provide information to pharmacists than technicians about the following topics: medical history, dosage and time of inhalation, and barriers. Technicians were more likely to give advice about ICS adherence than pharmacists.

### Lifestyle and social context information

Pharmacists gave information about the social context more often than technicians. Patients gave information to pharmacists more often than to technicians about physical activity and the (living) environment.

### Psychosocial information/feelings

Pharmacists and technicians differed in giving information regarding concerns about ICS, which was mentioned on average less than once a session. Patients also differed in giving information about this topic; they talked more often about ICS concerns in sessions with pharmacists than in sessions with technicians.

Number of sessions in which topics were discussed
-------------------------------------------------

Several clinically relevant topics were not discussed during many of the counseling sessions ([Table S2](#SD2-ppa-10-2239){ref-type="supplementary-material"}). The comparison between pharmacists and technicians revealed that questions about current health status were asked more often by pharmacists than by technicians, in 26 versus eleven sessions, respectively. Pharmacists gave an explanation about asthma more than once in 22 sessions; technicians did so in three sessions. Pharmacists paid attention more than once to the reason for ICS use in 26 sessions and to dosage in 55 sessions, whereas technicians only did so in 12 and 25 sessions, respectively. Technicians asked more than once about side effects in 42 sessions, whereas pharmacists did so in 29 sessions. Lifestyle/social categories were hardly mentioned. Smoking, the (living) environment, and the social context were discussed in a couple of sessions. In addition, psychosocial aspects or feelings were seldom discussed.

Outcomes controlled for visit length
------------------------------------

As stated before, pharmacists' sessions lasted longer than those of technicians. After controlling for visit length, most of the differences between pharmacists and technicians in communication behaviors remained significant. This was also the case for the differences found in patient communication during sessions with pharmacists and technicians after controlling for visit length ([Table S3](#SD3-ppa-10-2239){ref-type="supplementary-material"}).

After controlling for visit length, differences between pharmacists' and technicians' communication remained significant for the following affective categories: social behavior, approval, verbal attention, showing concerns/worry, and disagreeing. The differences in the number of questions about current health status, heredity, "medical, other", side effects, "lifestyle, other", and "other" also remained significant. In addition, differences in paraphrasing/checking for understanding and giving information about the lung function test, explanation about asthma/COPD, dosage, medicinal effects, and ICS concerns were still significant after controlling for visit length, as well as counseling about adherence.

For patient utterances, the number of questions about dosage, giving information about medical history, the (living) environment, and ICS concerns still differed between sessions with pharmacists and technicians after controlling for visit length.

Discussion
==========

Many important issues were addressed during the counseling sessions. However, pharmacists and technicians could pay more attention to some topics. Some differences in communication have been found between pharmacists and pharmacy technicians.

The counseling sessions consisted largely of instrumental talk. Medical and therapeutic topics were frequently discussed, such as current health status, inhaler and inhalation technique, side effects, dosage and time of inhalation, and ICS medicinal effects. Pharmacists and pharmacy technicians discussed adherence to a limited degree only. In this respect, counseling sessions reflect those of other health care providers: this topic is often avoided during patient--provider interactions.[@b21-ppa-10-2239],[@b31-ppa-10-2239]

Lifestyle and psychosocial issues were hardly addressed by pharmacists and technicians, while patients did mention these topics. As concerns have relevance for adherence to medication,[@b18-ppa-10-2239],[@b39-ppa-10-2239] there might be room for improvement in discussing patients' concerns about ICS and why it is necessary to use them. Pharmacists and technicians could also pay more attention to lifestyle topics, such as smoking habits and exercise.

Pharmacists and technicians talked with the patients extensively about the inhaler and inhalation technique, clearly the main aim of the session. In addition, medication other than ICS (the category "non-ICS treatment") was often discussed, such as bronchodilators (relievers). Because bronchodilators are often used in combination with ICS, pharmacists and technicians probably discuss these to check the inhalation technique as well as the effectiveness of the medication.

Remarkably, patients raised very few questions. On average, they only asked questions about the inhaler and inhalation technique more than once per session. This suggests either that they did not have much to ask or that there was not enough opportunity to pose questions. Pharmacists and technicians could invite patients more explicitly to ask questions.

An important aspect concerning pharmacist--patient communication is the way patients view the pharmacists' role (ie, tasks and responsibilities). A few studies have shown that some groups of patients have positive views about pharmacists' enhanced role in disease management and medication advice.[@b40-ppa-10-2239],[@b41-ppa-10-2239] However, other studies have found that patients do not perceive pharmacists as having a significant role in patient counseling, medication management, or monitoring; patients believe this to be primarily the task of physicians.[@b42-ppa-10-2239]--[@b44-ppa-10-2239] These findings could be a reason for patients' possible reticence in posing questions and discussing medical, lifestyle, and psychosocial issues.

When comparing pharmacists' and technicians' sessions, pharmacists showed more affective behavior than technicians, and they also discussed some task-oriented topics more extensively. Although pharmacists' sessions lasted 1.5 times longer than those of technicians, these differences could not be fully explained by the longer visit length of the pharmacists' sessions. In contrast to pharmacists and technicians, patients did not differ in their affective and process-oriented communications when being counseled by one or the other professional.

Pharmacist and pharmacy technicians spoke more than patients (55.0% and 53.2% of the utterances, respectively). Although this indicates that the providers made a greater conversational contribution than patients, we think the share of provider--patient communication is fairly balanced because the percentages are close to the middle (ie, 50%).

We can compare our findings with only a few studies. Because of dissimilarities in study setting and health care providers, these findings are difficult to compare. When comparing our findings with general practitioner--patient communication, no remarkable differences were found. Pharmacists and technicians in our study showed \~5% more affective behavior than general practitioners, which could be explained to a large extent by the many agreements that pharmacists and technicians expressed.[@b20-ppa-10-2239] General practitioners did not discuss lifestyle/social and psychosocial topics in much depth; however, pharmacists and technicians discussed them even less. Our findings also confirm the results of a simulated patient study of Chong et al[@b25-ppa-10-2239] about antidepressants, which showed that pharmacists' communication is merely focused on biomedical topics and that lifestyle and psychosocial topics are underexposed.

To our knowledge, this is the first study about communication during counseling sessions about ICS in the pharmacy. For future research, it would be interesting to study the relationship between the communication process and content on the one hand and outcomes on the other hand, such as patients' medication adherence, satisfaction, and symptom control. In addition, the experiences of patients and health care providers with the communication could be taken into account, to get insight into which communication styles enhance medication optimization, according to them.

Strengths and limitations
-------------------------

This study has several strengths. First, exploring the content of counseling sessions at the pharmacy has never been done before in such an extensive way, resulting in rich information about these sessions and an objective and quantitative presentation of the content of the verbal communication. In addition, this study did not only take pharmacists' communication into account but also looked at technicians' communication and compared the content of the sessions of these two categories of professionals.

However, there are some limitations. Selection bias could have occurred during pharmacy and patient recruitment. Participating pharmacies could be more engaged in patient counseling than the nonparticipating pharmacies, and participating patients might be more willing to communicate about ICS use, related problems, and feelings. In the Netherlands, counseling sessions are not yet routine activities in pharmacies,[@b23-ppa-10-2239] which implies that, in general, pharmacists and technicians are not very experienced in conducting counseling sessions about ICS. Therefore, the participating pharmacists and technicians might have better counseling skills than their nonparticipating colleagues. Hence, the generalizability of the findings is limited.

In addition, the pharmacists sent the invitation letter to patients. This might have resulted in bias as patients might feel obligated to participate in the study. However, it was stated clearly in the letter that participation was voluntary.

Finally, because counseling sessions are not performed very frequently, we provided general instructions to the pharmacists and technicians about which themes could be discussed during the sessions. Although these instructions were very broad, they might have influenced our results.

Conclusion
==========

Both pharmacists and pharmacy technicians addressed many important medical and therapeutic topics in counseling sessions with patients with asthma and/or COPD, but they could pay more attention to ICS adherence and to lifestyle and psychosocial topics. The two categories of professionals differed in their communication: pharmacists exhibited more affective behavior than technicians and also discussed medical and therapeutic topics in particular more extensively.

Practice implications
---------------------

Educational courses for pharmacists and pharmacy technicians could draw attention to the discussion of ICS adherence, lifestyle, and psychosocial topics in patient communication. Pharmacy technicians in particular could be encouraged to attend to other factors than purely the technical aspects of using ICS.

Supplementary materials
=======================

###### 

Examples of statements for RIAS categories

  -------------------------------------------------------------------------------------------------------------------
  RIAS category                               Examples of statements
  ------------------------------------------- -----------------------------------------------------------------------
  Affective part                              

   Social behavior                            At the beginning of the session: Pharmacist: "How are you?"

   Approval                                   (Patient shows inhaler technique) Pharmacist: "That looks very good!"

   Agreements                                 "Hmm, hmm" "Okay"

   Verbal attention                           Pharmacist: "I understand how you must be feeling"

   Shows concern or worry                     Patient: "I hope it's nothing serious"

    (Ask for) reassurance                     Patient: "My asthma is much better"

   Disagree                                   Patient: "That's impossible!"

  Instrumental part                           

   Process-oriented                           

    Orientations                              Pharmacist: "Can you show me how you use your inhaler, please?"

    Paraphrase/check for understanding        (Pharmacist: "You have to hold your breath for ten seconds")\
                                              Patient: "Ten seconds?"

    Bid for repetition                        Patient: "What did you say?"

    Ask for understanding                     Pharmacist: "Do you follow?"

    Ask for opinion                           Pharmacist: "Any questions?"

    Request for services (patient category)   Patient: "Could you contact the doctor for this, please?"

   Task-oriented communication                

    Medical                                   Pharmacist: "Do you have asthma?"

    Therapeutic                               Patient: "I take two puffs per day"

    Lifestyle/social                          Pharmacist: "Do you smoke?"

    Psychosocial/feelings                     Patient: "I'm worried about the long-term effects of ICS"

    Other                                     Patient: "Where can I fill in the questionnaire?"
  -------------------------------------------------------------------------------------------------------------------

**Abbreviations:** RIAS, Roter interaction analysis system; ICS, inhaled corticosteroids.

###### 

The number of sessions in which a topic is discussed zero times, once, or more than once (divided into questions, giving information, and counseling)

                                                          Question   Giving information   Counseling                            
  ------------------------------------------------------- ---------- -------------------- ------------ ---- ---- ---- ---- ---- ----
  **Medical**                                                                                                                   
  Prevalence                                                                                                                    
   Pharmacists                                            86         0                    0            85   0    1    86   0    0
   Technicians                                            83         0                    0            83   0    0    83   0    0
  Prognosis                                                                                                                     
   Pharmacists                                            86         0                    0            84   2    0    86   0    0
   Technicians                                            83         0                    0            83   0    0    83   0    0
  Exacerbations                                                                                                                 
   Pharmacists                                            82         3                    1            83   2    1    86   0    0
   Technicians                                            83         0                    0            82   0    1    83   0    0
  Current health status                                                                                                         
   Pharmacists                                            40         17                   29           35   22   29   86   0    0
   Technicians                                            49         23                   11           41   20   22   82   1    0
  Medical history                                                                                                               
   Pharmacists                                            65         13                   8            69   10   7    86   0    0
   Technicians                                            69         10                   4            72   8    3    83   0    0
  Heredity                                                                                                                      
   Pharmacists                                            86         0                    0            84   1    1    86   0    0
   Technicians                                            77         4                    2            79   2    2    83   0    0
  Contact other health care providers about asthma/COPD                                                                         
   Pharmacists                                            60         15                   11           64   12   10   78   4    4
   Technicians                                            56         16                   11           69   7    7    70   7    6
  Lung function test                                                                                                            
   Pharmacists                                            72         8                    6            62   10   14   81   1    4
   Technicians                                            78         4                    1            74   5    4    83   0    0
  Explanation about asthma/COPD                                                                                                 
   Pharmacists                                            85         1                    0            59   5    22   86   0    0
   Technicians                                            83         0                    0            79   1    3    83   0    0
  Medical, other                                                                                                                
   Pharmacists                                            56         10                   20           45   10   31   77   6    3
   Technicians                                            69         6                    8            55   9    19   80   2    1
  **Therapeutic: ICS treatment**                                                                                                
  Reason for use/need                                                                                                           
   Pharmacists                                            54         25                   7            45   15   26   82   4    0
   Technicians                                            64         18                   1            59   12   12   81   1    1
  Dosage/inhalation                                                                                                             
   Pharmacists                                            31         22                   33           18   13   55   59   11   16
   Technicians                                            32         29                   22           36   22   25   62   13   8
  Adherence                                                                                                                     
   Pharmacists                                            60         19                   7            45   16   25   76   8    2
   Technicians                                            55         21                   7            49   12   22   67   8    8
  Medicinal effects                                                                                                             
   Pharmacists                                            40         25                   21           10   8    68   84   2    0
   Technicians                                            43         22                   18           13   16   54   83   0    0
  Side effects                                                                                                                  
   Pharmacists                                            30         27                   29           26   10   50   78   5    3
   Technicians                                            16         25                   42           18   9    56   81   1    1
  Inhaler/inhalation                                                                                                            
   Pharmacists                                            5          8                    73           2    3    81   13   4    69
   Technicians                                            5          4                    74           0    1    82   7    7    69
  Contact other health care providers about ICS                                                                                 
   Pharmacists                                            62         17                   7            68   8    10   65   7    14
   Technicians                                            57         15                   11           60   14   9    62   12   9
  Self-management                                                                                                               
   Pharmacists                                            82         4                    0            79   3    4    85   1    0
   Technicians                                            83         0                    0            81   0    2    83   0    0
  Facilitators                                                                                                                  
   Pharmacists                                            83         1                    2            61   6    19   85   1    0
   Technicians                                            74         7                    2            59   11   13   83   0    0
  Barriers                                                                                                                      
   Pharmacists                                            83         2                    1            66   6    14   86   0    0
   Technicians                                            80         3                    0            71   3    9    83   0    0
  ICS, other                                                                                                                    
   Pharmacists                                            49         22                   15           28   18   40   82   3    1
   Technicians                                            44         29                   10           38   14   31   78   5    0
  **Therapeutic: non-ICS treatment**                                                                                            
   Pharmacists                                            22         18                   46           14   6    66   56   13   17
   Technicians                                            31         16                   36           14   9    60   55   11   17
  **Lifestyle/social**                                                                                                          
  Smoking                                                                                                                       
   Pharmacists                                            72         8                    6            74   6    6    83   3    0
   Technicians                                            73         6                    4            78   3    2    83   0    0
  Exercise                                                                                                                      
   Pharmacists                                            83         2                    1            71   11   4    82   2    2
   Technicians                                            80         3                    0            79   2    2    82   0    1
  Weight                                                                                                                        
   Pharmacists                                            86         0                    0            86   0    0    86   0    0
   Technicians                                            83         0                    0            83   0    0    83   0    0
  Nutrition                                                                                                                     
   Pharmacists                                            85         1                    0            83   2    1    85   1    0
   Technicians                                            83         0                    0            81   2    0    83   0    0
  Stress                                                                                                                        
   Pharmacists                                            86         0                    0            86   0    0    86   0    0
   Technicians                                            83         0                    0            81   2    0    83   0    0
  Drugs                                                                                                                         
   Pharmacists                                            85         0                    1            85   0    1    86   0    0
   Technicians                                            83         0                    0            83   0    0    83   0    0
  Influenza vaccine                                                                                                             
   Pharmacists                                            84         2                    0            86   0    0    86   0    0
   Technicians                                            83         0                    0            82   0    1    83   0    0
  (Living) environment                                                                                                          
   Pharmacists                                            77         6                    3            62   9    15   85   1    0
   Technicians                                            75         5                    3            66   7    10   83   0    0
  Social context                                                                                                                
   Pharmacists                                            80         6                    0            63   5    18   85   1    0
   Technicians                                            81         2                    0            66   4    13   81   1    1
  Lifestyle, other                                                                                                              
   Pharmacists                                            78         5                    3            73   7    6    84   2    0
   Technicians                                            82         1                    0            73   7    3    83   0    0
  **Psychosocial/feelings**                                                                                                     
  ICS concerns                                                                                                                  
   Pharmacists                                            85         1                    0            79   4    3    86   0    0
   Technicians                                            83         0                    0            82   1    0    83   0    0
  ICS necessities                                                                                                               
   Pharmacists                                            86         0                    0            82   1    3    86   0    0
   Technicians                                            83         0                    0            77   5    1    83   0    0
  Psychosocial ICS, other                                                                                                       
   Pharmacists                                            65         17                   4            65   8    13   84   1    1
   Technicians                                            71         8                    4            54   18   11   83   0    0
  Non-ICS                                                                                                                       
   Pharmacists                                            85         1                    0            75   5    6    86   0    0
   Technicians                                            81         1                    1            72   6    5    83   0    0
  Other                                                                                                                         
   Pharmacists                                            66         11                   9            0    0    86   85   1    0
   Technicians                                            79         4                    0            0    0    83   83   0    0

**Abbreviations:** COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids.

###### 

Weighted mean (SE) of behaviors of pharmacists, pharmacy technicians, and patients, controlled for visit length

                                         Pharmacists' and technicians' behavior                         Patients' behavior                                                                                                        
  -------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Affective part                                                                                                                                                                                                                  
   Social behavior                       2.11 (0.29)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       1.22 (0.29)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
   Approval                              1.69 (0.17)[\*\*](#tfn26-ppa-10-2239){ref-type="table-fn"}     1.29 (0.67)[\*\*](#tfn26-ppa-10-2239){ref-type="table-fn"}     --                                                         --
   Agreements                            13.86 (1.02)                                                   14.36 (1.02)                                                   12.07 (0.54)                                               12.36 (0.55)
   Verbal attention                      0.87 (0.11)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   0.47 (0.11)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   --                                                         --
   Shows concern or worry                0.09 (0.02)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.03 (0.02)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
   Reassurance                           1.79 (0.15)                                                    1.76 (0.15)                                                    --                                                         --
   Disagree                              0.05 (0.01)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.02 (0.01)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
  Instrumental part                                                                                                                                                                                                               
   Process-oriented                                                                                                                                                                                                               
    Paraphrase/check for understanding   4.06 (0.35)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       4.76 (0.35)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
   Task-oriented                                                                                                                                                                                                                  
    Question                                                                                                                                                                                                                      
     Medical                                                                                                                                                                                                                      
      Current health status              0.30 (0.05)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.18 (0.05)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
      Heredity                           −0.00 (0.02)[\*\*](#tfn26-ppa-10-2239){ref-type="table-fn"}    0.03 (0.02)[\*\*](#tfn26-ppa-10-2239){ref-type="table-fn"}     --                                                         --
      Medical, other                     0.21 (0.05)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.09 (0.05)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
     ICS treatment                                                                                                                                                                                                                
      Reason for use/need                0.12 (0.03)                                                    0.08 (0.03)                                                    --                                                         --
      Dosage                             --                                                             --                                                             0.08 (0.02)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}   0.02 (0.02)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}
      Side-effects                       0.35 (0.09)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   0.69 (0.09)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   --                                                         --
      Self-management                    0.01 (0.01)                                                    0.00 (0.01)                                                    --                                                         --
     Non-ICS treatment                   0.54 (0.09)                                                    0.54 (0.09)                                                    --                                                         --
     Lifestyle/social                                                                                                                                                                                                             
      Social context                     --                                                             --                                                             0.01 (0.00)                                                0.00 (0.00)
      Lifestyle, other                   0.03 (0.01)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.00 (0.01)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
     Other                               0.10 (0.02)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   0.02 (0.02)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   --                                                         --
    Give information                                                                                                                                                                                                              
     Medical                                                                                                                                                                                                                      
      Medical history                    --                                                             --                                                             1.00 (0.12)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}   0.63 (0.13)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}
      Lung function test                 0.22 (0.08)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.03 (0.08)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --
      Explanation about asthma/COPD      0.49 (0.10)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   0.02 (0.10)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}                                                              
     ICS treatment                                                                                                                                                                                                                
      Reason for use/need                0.24 (0.04)                                                    0.16 (0.04)                                                    --                                                         --
      Dosage                             0.76 (0.09)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   0.39 (0.09)[\*\*\*](#tfn27-ppa-10-2239){ref-type="table-fn"}   1.38 (0.14)                                                1.30 (0.14)
      Medicinal effects                  1.67 (0.15)[\*\*](#tfn26-ppa-10-2239){ref-type="table-fn"}     1.07 (0.15)[\*\*](#tfn26-ppa-10-2239){ref-type="table-fn"}     --                                                         --
      Inhaler/inhalation                 6.02 (0.55)                                                    6.09 (0.55)                                                    --                                                         --
      Barriers                           --                                                             --                                                             0.19 (0.04)                                                0.09 (0.04)
     Non-ICS treatment                   2.63 (0.30)                                                    2.09 (0.31)                                                    --                                                         --
     Lifestyle/social                                                                                                                                                                                                             
       (Living) environment              --                                                             --                                                             0.35 (0.06)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}   0.22 (0.06)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}
      Social context                     0.25 (0.06)                                                    0.16 (0.06)                                                    --                                                         --
     Psychosocial/feelings                                                                                                                                                                                                        
      ICS Concerns                       0.03 (0.01)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.00 (0.01)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.23 (0.05)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}   0.11 (0.05)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}
     Other                               4.79 (0.40)                                                    4.82 (0.40)                                                    4.10 (0.32)                                                3.68 (0.32)
    Counsel                                                                                                                                                                                                                       
     ICS treatment                                                                                                                                                                                                                
      Adherence                          0.05 (0.04)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       0.13 (0.04)[\*](#tfn25-ppa-10-2239){ref-type="table-fn"}       --                                                         --

**Notes:**

Significant at *P*\<0.05.

Significant at *P*\<0.01.

Significant at *P*\<0.001.

**Abbreviations:** SE, standard error; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids.
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###### 

Patient, pharmacist, and pharmacy technician characteristics and summary of pharmacist--patient and technician--patient communication

                                                                                                              Pharmacist--patient sessions n=86   Technician--patient sessions n=83   Total n=169                
  ----------------------------------------------------------------------------------------------------------- ----------------------------------- ----------------------------------- -------------------------- -------------
  Patient characteristics                                                                                                                                                                                        
   Female                                                                                                     47 (54.7%)                          46 (55.4%)                          93 (55.0%)                 
   Age, years                                                                                                                                                                                                    
    Mean (years) ± SD (range)                                                                                 63.7±13.4 (26--88)                  62.5±14.5 (28--87)                  63.1±13.9 (26--88)         
   Age group, years                                                                                                                                                                                              
    18--44                                                                                                    8 (9.3%)                            12 (14.5%)                          20 (11.8%)                 
    45--64                                                                                                    32 (37.2%)                          29 (34.9%)                          61 (36.1%)                 
    \>64                                                                                                      46 (53.5%)                          42 (50.6%)                          88 (52.1%)                 
   Educational level[a](#tfn1-ppa-10-2239){ref-type="table-fn"},[b](#tfn2-ppa-10-2239){ref-type="table-fn"}                                                                                                      
    Low                                                                                                       33 (38.4%)                          37 (44.6%)                          70 (41.4%)                 
    Intermediate                                                                                              17 (19.8%)                          16 (19.3%)                          33 (19.5%)                 
    High                                                                                                      35 (40.7%)                          29 (34.9%)                          64 (37.9%)                 
   Diagnosis[c](#tfn3-ppa-10-2239){ref-type="table-fn"}                                                                                                                                                          
    Asthma                                                                                                    34 (39.5%)                          34 (41.0%)                          68 (40.2%)                 
    COPD                                                                                                      21 (24.4%)                          21 (25.3%)                          42 (24.9%)                 
    Asthma and COPD                                                                                           17 (19.8%)                          16 (19.3%)                          33 (19.5%)                 
    Unknown                                                                                                   14 (16.3%)                          12 (14.5%)                          26 (15.4%)                 
                                                                                                                                                                                                                 
                                                                                                              **Pharmacists n**=**12**            **Pharmacy technicians n**=**12**                              
                                                                                                                                                                                                                 
  Pharmacist and pharmacy technician characteristics                                                                                                                                                             
   Age group, years                                                                                                                                                                                              
    Mean (years) ± SD (range)                                                                                 36.7±11.5 (24--57)                  35.4±11.9 (23--53)                                             
   Female                                                                                                     6 (50%)                             12 (100%)                                                      
   Number of years since graduating                                                                                                                                                                              
    Mean (years) ± SD (range)                                                                                 11.1±10.4 (0--32)                   14.4±11.8 (2--34)                                              
  Pharmacist--patient and pharmacy technician--patient communication                                                                                                                                             
                                                                                                                                                                                                                 
                                                                                                              **Pharmacist**                      **Patient**                         **Technician**             **Patient**
                                                                                                                                                                                                                 
  Total communication[d](#tfn4-ppa-10-2239){ref-type="table-fn"}                                              55.0%                               45.0%                               53.2%                      46.8%
   Affective communication                                                                                    20.2%                               16.7%                               19.4%                      16.3%
   Instrumental communication                                                                                 34.8%                               28.3%                               33.8%                      30.5%
  Session length                                                                                                                                                                                                 
   Mean[e](#tfn5-ppa-10-2239){ref-type="table-fn"} (minutes) ± SE (range)                                     16.46±0.80 (5.42--33.30)                                                11.34±0.80 (4.23--26.73)   

**Notes:**

Two missing.

Low: no education, primary school, prevocational secondary education (VMBO), lower vocational secondary education (LBO), junior general secondary education (MULO/MAVO); intermediate: upper vocational secondary education (MBO), senior general secondary education (HAVO), preuniversity education (VWO); high: university of applied sciences (HBO), university (WO).

Diagnosis based on self-report.

Percentages are based on weighted mean.

Weighted mean.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; SE, standard error.

###### 

Weighted mean (SE) of affective behaviors and process-oriented behaviors of pharmacists, technicians, and patients in counseling sessions

                                                                 Pharmacists' and technicians' behavior                          Patients' behavior                                                                                                            
  -------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------
  Affective part[a](#tfn7-ppa-10-2239){ref-type="table-fn"}      89.02 (5.48)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}        63.72 (5.53)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}        73.55 (5.06)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}   53.66 (5.12)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}
   Social behavior                                               10.55 (1.68)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}     4.86 (1.70)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}      10.47 (2.01)                                                  6.52 (2.04)
   Approval                                                      6.91 (0.56)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}         3.68 (0.56)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}         1.70 (0.24)                                                   1.45 (0.24)
   Agreements                                                    59.95 (4.91)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}     48.50 (4.94)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}     54.54 (3.67)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}      39.61 (3.71)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}
   Verbal attention                                              3.91 (0.56)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}      2.00 (0.57)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}      0.12 (0.04)                                                   0.06 (0.04)
   Shows concern or worry                                        0.44 (0.09)[\*\*\*](#tfn11-ppa-10-2239){ref-type="table-fn"}    0.15 (0.10)[\*\*\*](#tfn11-ppa-10-2239){ref-type="table-fn"}    1.95 (0.37)                                                   1.37 (0.38)
   Reassurance                                                   7.77 (0.62)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}         5.16 (0.63)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}         3.82 (0.42)                                                   3.40 (0.43)
   Disagree                                                      0.24 (0.05)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}      0.05 (0.05)[\*\*](#tfn10-ppa-10-2239){ref-type="table-fn"}      0.95 (0.57)                                                   1.39 (0.57)
  Instrumental part                                                                                                                                                                                                                                            
   Process-oriented[a](#tfn7-ppa-10-2239){ref-type="table-fn"}   28.63 (2.15)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}        21.45 (2.16)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}        4.69 (0.62)                                                   4.08 (0.62)
    Orientations[b](#tfn8-ppa-10-2239){ref-type="table-fn"}      8.26 (0.98)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}         4.15 (0.98)[\*](#tfn9-ppa-10-2239){ref-type="table-fn"}         0.28 (0.07)                                                   0.14 (0.07)
    Paraphrase/check for understanding                           17.91 (1.70)[\*\*\*](#tfn11-ppa-10-2239){ref-type="table-fn"}   15.25 (1.70)[\*\*\*](#tfn11-ppa-10-2239){ref-type="table-fn"}   4.19 (0.57)                                                   3.73 (0.57)
    Bid for repetition                                           0.04 (0.02)                                                     0.05 (0.02)                                                     0.14 (0.05)                                                   0.14 (0.05)
    Ask for understanding                                        0.56 (0.13)                                                     0.44 (0.13)                                                     0.06 (0.03)                                                   0.07 (0.03)
    Ask for opinion                                              1.89 (0.26)                                                     1.58 (0.26)                                                     0.00 (0.01)                                                   0.01 (0.01)
    Request for services (patient category)                      --                                                              --                                                              0.04 (0.02)                                                   0.00 (0.02)

**Notes:**

Totals have been calculated using the model and can be different from the total of individual categories.

Due to a low intraclass correlation coefficient (ICC), no results have been reported in this article for this category.

Significant at *P*\<0.001.

Significant at *P*\<0.01.

Significant at *P*\<0.05.

**Abbreviation:** SE, standard error.

###### 

Weighted mean (SE) of task-oriented behaviors of pharmacists and pharmacy technicians during counseling sessions

  Task-oriented communication                                                  Question                                                       Giving information                                             Counseling                                                                                                                                                                                     
  ---------------------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------
  Medical[a](#tfn13-ppa-10-2239){ref-type="table-fn"}                          3.42 (0.43)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       1.86 (0.43)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       9.25 (1.35)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        3.60 (1.36)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        0.50 (0.19)                                                    0.44 (0.19)
   Prevalence                                                                  0                                                              0                                                              0.06 (0.04)                                                     0.00 (0.04)                                                     0                                                              0
   Prognosis                                                                   0                                                              0                                                              0.02 (0.01)                                                     0.00 (0.01)                                                     0                                                              0
   Exacerbations                                                               0.06 (0.02)                                                    0.00 (0.02)                                                    0.06 (0.04)                                                     0.04 (0.04)                                                     0                                                              0
   Current health status                                                       1.31 (0.19)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       0.62 (0.19)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       1.87 (0.28)                                                     1.31 (0.28)                                                     0.00 (00.1)                                                    0.01 (0.01)
   Medical history                                                             0.37 (0.10)                                                    0.20 (0.10)                                                    0.31 (0.08)                                                     0.22 (0.08)                                                     0                                                              0
   Heredity                                                                    0.00 (0.05)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     0.09 (0.05)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     0.03 (0.05)                                                     0.09 (0.05)                                                     0                                                              0
   Contact other health care                                                   0.49 (0.10)                                                    0.54 (0.10)                                                    0.53 (0.14)                                                     0.37 (0.14)                                                     0.15 (0.11)                                                    0.39 (0.11)
   providers about asthma/COPD                                                                                                                                                                                                                                                                                                                                                                              
   Lung function test                                                          0.32 (0.10)                                                    0.08 (0.10)                                                    0.96 (0.32)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}      0.13 (0.32)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}      0.19 (0.08)                                                    0.00 (0.08)
   Explanation about asthma/COPD                                               0.01 (0.01)                                                    0.00 (0.01)                                                    2.65 (0.62)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        0.06 (0.63)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        0                                                              0
   Medical, other                                                              0.85 (0.21)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   0.33 (0.21)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   2.74 (0.58)                                                     1.47 (0.59)                                                     0.15 (0.04)                                                    0.05 (0.05)
  Therapeutic: ICS treatment[a](#tfn13-ppa-10-2239){ref-type="table-fn"}       10.97 (0.87)                                                   10.57 (0.87)                                                   46.53 (3.17)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       33.42 (3.20)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       11.25 (1.45)                                                   11.12 (1.46)
   Reason for use/need                                                         0.45 (0.10)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     0.20 (0.10)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     1.03 (0.14)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}    0.54 (0.14)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}    0.05 (0.03)                                                    0.05 (0.03)
   Dosage                                                                      1.27 (0.16)                                                    0.95 (0.16)                                                    3.30 (0.35)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        1.27 (0.35)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        0.86 (0.17)                                                    0.53 (0.17)
   Adherence                                                                   0.42 (0.10)                                                    0.45 (0.10)                                                    1.38 (0.26)                                                     1.21 (0.26)                                                     0.17 (0.14)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   0.49 (0.14)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}
   Medicinal effects                                                           1.11 (0.23)                                                    0.83 (0.23)                                                    7.36 (0.75)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        3.30 (0.76)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}        0.02 (0.01)                                                    0.00 (0.01)
   Side effects                                                                1.36 (0.29)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     1.90 (0.29)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     3.87 (0.56)                                                     3.84 (0.57)                                                     0.13 (0.04)                                                    0.05 (0.04)
   Inhaler/inhalation                                                          5.05 (0.48)                                                    4.76 (0.48)                                                    25.29 (2.24)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   19.50 (2.26)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   9.41 (1.41)                                                    9.49 (1.42)
   Contact other health care providers about ICS                               0.40 (0.10)                                                    0.55 (0.10)                                                    0.39 (0.10)                                                     0.48 (0.10)                                                     0.50 (0.12)                                                    0.47 (0.12)
   Self-management                                                             0.05 (0.02)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   0.00 (0.02)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   0.17 (0.07)                                                     0.07 (0.07)                                                     0.01 (0.01)                                                    0.00 (0.01)
   Facilitators                                                                0.07 (0.06)                                                    0.14 (0.06)                                                    0.88 (0.20)                                                     0.84 (0.20)                                                     0.01 (0.01)                                                    0.00 (0.01)
   Barriers                                                                    0.06 (0.03)                                                    0.04 (0.03)                                                    0.52 (0.12)                                                     0.36 (0.12)                                                     0                                                              0
   ICS, other                                                                  0.69 (0.12)                                                    0.71 (0.13)                                                    2.23 (0.47)                                                     1.99 (0.47)                                                     0.06 (0.03)                                                    0.06 (0.03)
  Therapeutic: non-ICS treatment[a](#tfn13-ppa-10-2239){ref-type="table-fn"}   2.31 (0.27)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   1.61 (0.27)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   12.34 (1.32)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     7.46 (1.34)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}      1.21 (0.31)                                                    1.33 (0.32)
  Lifestyle/social[a](#tfn13-ppa-10-2239){ref-type="table-fn"}                 0.74 (0.18)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   0.40 (0.18)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   3.31 (0.56)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}      1.43 (0.57)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}      0.17 (0.07)                                                    0.08 (0.07)
   Smoking                                                                     0.22 (0.10)                                                    0.19 (0.10)                                                    0.38 (0.14)                                                     0.18 (0.14)                                                     0.03 (0.02)                                                    0.00 (0.02)
   Exercise                                                                    0.05 (0.03)                                                    0.04 (0.03)                                                    0.43 (0.14)                                                     0.12 (0.14)                                                     0.08 (0.05)                                                    0.05 (0.05)
   Weight                                                                      0                                                              0                                                              0                                                               0                                                               0                                                              0
   Nutrition                                                                   0.02 (0.01)                                                    0.00 (0.01)                                                    0.11 (0.06)                                                     0.02 (0.06)                                                     0.01 (0.01)                                                    0.00 (0.01)
   Stress                                                                      0                                                              0                                                              0.00 (0.01)                                                     0.02 (0.01)                                                     0                                                              0
   Drugs                                                                       0.02 (0.02)                                                    0.00 (0.02)                                                    0.05 (0.03)                                                     0.00 (0.03)                                                     0                                                              0
   Influenza vaccine                                                           0.02 (0.01)                                                    0.00 (0.01)                                                    0.00 (0.03)                                                     0.04 (0.03)                                                     0                                                              0
   Living environment                                                          0.15 (0.07)                                                    0.14 (0.07)                                                    0.89 (0.27)                                                     0.41 (0.27)                                                     0.01 (0.01)                                                    0.00 (0.01)
   Social context                                                              0.07 (0.02)                                                    0.02 (0.02)                                                    1.20 (0.28)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}    0.52 (0.28)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}    0.01 (0.02)                                                    0.04 (0.02)
   Lifestyle, other                                                            0.19 (0.07)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   0.01 (0.07)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}   0.30 (0.09)                                                     0.17 (0.09)                                                     0.02 (0.01)                                                    0.00 (0.01)
  Psychosocial/feelings[a](#tfn13-ppa-10-2239){ref-type="table-fn"}            0.32 (0.08)                                                    0.25 (0.08)                                                    1.18 (0.26)                                                     1.09 (0.26)                                                     0.03 (0.02)                                                    0.00 (0.02)
   ICS concerns                                                                0.01 (0.01)                                                    0.00 (0.01)                                                    0.14 (0.04)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}    0.01 (0.04)[\*\*\*](#tfn16-ppa-10-2239){ref-type="table-fn"}    0                                                              0
   ICS necessities                                                             0                                                              0                                                              0.08 (0.04)                                                     0.10 (0.04)                                                     0                                                              0
   Psychosocial ICS, other                                                     0.30 (0.07)                                                    0.20 (0.07)                                                    0.66 (0.15)                                                     0.59 (0.15)                                                     0.03 (0.02)                                                    0.00 (0.02)
   Non-ICS                                                                     0.01 (0.03)                                                    0.05 (0.03)                                                    0.29 (0.13)                                                     0.39 (0.13)                                                     0                                                              0
  Other                                                                        0.41 (0.08)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       0.04 (0.08)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       20.72 (1.52)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     15.09 (1.54)[\*\*](#tfn15-ppa-10-2239){ref-type="table-fn"}     0.01 (0.01)                                                    0.00 (0.01)
  Total[a](#tfn13-ppa-10-2239){ref-type="table-fn"}                            18.15 (1.22)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}      14.70 (1.22)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}      93.31 (5.57)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       61.87 (5.61)[\*](#tfn14-ppa-10-2239){ref-type="table-fn"}       13.13 (1.57)                                                   12.90 (1.58)

**Notes:**

Totals have been calculated using the model and can be different from the total of individual categories.

Significant at *P*\<0.001.

Significant at *P*\<0.01.

Significant at *P*\<0.05.

**Abbreviations:** SE, standard error; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids.

###### 

Weighted mean (SE) of task-oriented behaviors of patients in sessions with pharmacists and pharmacy technicians

  Task-oriented communication                                                  Question                                                     Giving information                                                                                                            
  ---------------------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ ---------------------------------------------------------------- ---------------------------------------------------------------
  Medical[a](#tfn18-ppa-10-2239){ref-type="table-fn"}                          0.33 (0.07)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}     0.12 (0.07)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}     22.94 (2.20)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}        17.01 (2.24)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}
   Prevalence                                                                  0.01 (0.01)                                                  0.00 (0.01)                                                  0                                                                0
   Prognosis                                                                   0                                                            0                                                            0                                                                0
   Exacerbations                                                               0                                                            0                                                            0.21 (0.10)                                                      0.15 (0.10)
   Current health status                                                       0.06 (0.03)                                                  0.06 (0.03)                                                  5.52 (0.53)                                                      4.31 (0.53)
   Medical history                                                             0.03 (0.02)                                                  0.01 (0.02)                                                  5.01 (0.66)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}       2.24 (0.68)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}
   Heredity                                                                    0                                                            0                                                            0.11 (0.12)                                                      0.30 (0.12)
   Contact other health care providers about asthma/COPD                       0.02 (0.01)                                                  0.01 (0.01)                                                  2.83 (0.41)                                                      2.46 (0.42)
   Lung function test                                                          0.08 (0.06)                                                  0.02 (0.06)                                                  1.86 (0.35)                                                      0.99 (0.36)
   Explanation about asthma/COPD                                               0.07 (0.03)                                                  0.00 (0.03)                                                  0.15 (0.05)                                                      0.06 (0.05)
   Medical, other                                                              0.06 (0.02)                                                  0.02 (0.02)                                                  7.33 (1.47)                                                      6.62 (1.49)
  Therapeutic: ICS treatment[a](#tfn18-ppa-10-2239){ref-type="table-fn"}       2.62 (0.35)                                                  2.28 (0.36)                                                  44.19 (3.08)                                                     40.72 (3.10)
   Reason for use/need                                                         0.06 (0.05)                                                  0.07 (0.05)                                                  1.19 (0.18)                                                      1.00 (0.18)
   Dosage                                                                      0.36 (0.10)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}     0.08 (0.10)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}     5.67 (0.49)[\*\*\*](#tfn21-ppa-10-2239){ref-type="table-fn"}     3.92 (0.49)[\*\*\*](#tfn21-ppa-10-2239){ref-type="table-fn"}
   Adherence                                                                   0.04 (0.02)                                                  0.01 (0.02)                                                  1.95 (0.31)                                                      1.43 (0.31)
   Medicinal effects                                                           0.15 (0.04)                                                  0.05 (0.04)                                                  2.44 (0.38)                                                      1.82 (0.39)
   Side-effects                                                                0.24 (0.08)                                                  0.23 (0.08)                                                  3.86 (0.57)                                                      3.91 (0.58)
   Inhaler/inhalation                                                          1.52 (0.26)                                                  1.64 (0.26)                                                  22.76 (2.11)                                                     22.64 (2.12)
   Contact other health care providers about ICS                               0.08 (0.02)                                                  0.02 (0.02)                                                  1.62 (0.30)                                                      2.11 (0.30)
   Self-management                                                             0                                                            0                                                            0.16 (0.09)                                                      0.29 (0.09)
   Facilitators                                                                0.01 (0.01)                                                  0.01 (0.01)                                                  0.51 (0.15)                                                      0.56 (0.15)
   Barriers                                                                    0.02 (0.02)                                                  0.02 (0.02)                                                  0.92 (0.19)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}         0.34 (0.19)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}
   ICS, other                                                                  0.14 (0.04)                                                  0.13 (0.04)                                                  2.81 (0.29)                                                      2.47 (0.29)
  Therapeutic: Non-ICS treatment[a](#tfn18-ppa-10-2239){ref-type="table-fn"}   0.74 (0.15)                                                  0.59 (0.15)                                                  15.21 (1.49)                                                     12.40 (1.52)
  Lifestyle/social[a](#tfn18-ppa-10-2239){ref-type="table-fn"}                 0.17 (0.05)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}   0.00 (0.05)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}   9.29 (1.43)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}         5.74 (1.45)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}
   Smoking                                                                     0                                                            0                                                            0.99 (0.31)                                                      0.62 (0.31)
   Exercise                                                                    0.05 (0.02)                                                  0.00 (0.02)                                                  1.99 (0.34)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}         1.01 (0.35)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}
   Weight                                                                      0                                                            0                                                            0.00 (0.09)                                                      0.18 (0.09)
   Nutrition                                                                   0                                                            0                                                            0.30 (0.19)                                                      0.33 (0.19)
   Stress                                                                      0                                                            0                                                            0.01 (0.03)                                                      0.04 (0.03)
   Drugs                                                                       0                                                            0                                                            0.16 (0.08)                                                      0.00 (0.08)
   Influenza vaccine                                                           0                                                            0                                                            0.04 (0.06)                                                      0.18 (0.06)
    (Living) environment                                                       0.07 (0.04)                                                  0.00 (0.04)                                                  1.52 (0.25)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}       0.70 (0.25)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}
   Social context                                                              0.05 (0.02)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}     0.00 (0.02)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}     2.75 (0.67)                                                      1.60 (0.68)
   Lifestyle, other                                                            0.01 (0.01)                                                  0.00 (0.01)                                                  1.43 (0.37)                                                      0.96 (0.37)
  Psychosocial/feelings[a](#tfn18-ppa-10-2239){ref-type="table-fn"}            0.09 (0.04)                                                  0.05 (0.04)                                                  5.84 (0.78)                                                      5.37 (0.79)
   ICS concerns                                                                0.05 (0.02)                                                  0.02 (0.02)                                                  0.98 (0.21)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}         0.45 (0.21)[\*](#tfn19-ppa-10-2239){ref-type="table-fn"}
   ICS necessities                                                             0.02 (0.01)                                                  0.00 (0.01)                                                  0.51 (0.13)                                                      0.44 (0.13)
   Psychosocial ICS, other                                                     0.02 (0.01)                                                  0.01 (0.01)                                                  2.14 (0.37)                                                      2.05 (0.37)
   Non-ICS                                                                     0.00 (0.01)                                                  0.01 (0.01)                                                  2.15 (0.55)                                                      2.39 (0.56)
  Other                                                                        0.44 (0.09)                                                  0.21 (0.09)                                                  17.92 (1.31)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}      11.89 (1.34)[\*\*](#tfn20-ppa-10-2239){ref-type="table-fn"}
  Total[a](#tfn18-ppa-10-2239){ref-type="table-fn"}                            4.38 (0.49)                                                  3.22 (0.50)                                                  115.40 (6.28)[\*\*\*](#tfn21-ppa-10-2239){ref-type="table-fn"}   92.77 (6.36)[\*\*\*](#tfn21-ppa-10-2239){ref-type="table-fn"}

**Notes:**

Totals have been calculated in the model and can be different from the total of individual categories.

Significant at *P*\<0.05.

Significant at *P*\<0.01.

Significant at *P*\<0.001.

**Abbreviations:** SE, standard error; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids.
